MEF2D, myocyte enhancer factor 2D, 4209

N. diseases: 72; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0338480
Disease: Common Migraine
Common Migraine 		0.330 Biomarker disease BEFREE MEF2D, PRDM16 and ASTN2 were also found to be associated with migraine without aura (MO) and migraine with family history. 28058730 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.040 Biomarker group BEFREE MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases. 28340574 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.040 Biomarker group BEFREE MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases. 28340574 2017
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.040 Biomarker disease BEFREE MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases. 28340574 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 Biomarker disease BEFREE MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases. 28340574 2017
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 Biomarker disease BEFREE MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases. 28340574 2017
CUI: C0035204
Disease: Respiration Disorders
Respiration Disorders 		0.010 Biomarker group BEFREE MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases. 28340574 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.010 Biomarker phenotype BEFREE Myocyte enhancer factor 2D (MEF2D) is involved in many aspects of cancer progression, including cell proliferation, invasion, and migration. 28478181 2017
CUI: C1519670
Disease: Tumor Angiogenesis
Tumor Angiogenesis 		0.010 Biomarker phenotype BEFREE MEF2D was found to be a downstream effector of hypoxia-inducible factor (HIF)-1α in the induction of tumor angiogenesis. 28478181 2017
CUI: C0220630
Disease: Adult Liver Carcinoma
Adult Liver Carcinoma 		0.030 Biomarker disease BEFREE Myocyte enhancer factor 2D (MEF2D), an oncogene in liver cancer, has been shown to be aberrantly expressed in lung cancer. 29963192 2018
CUI: C0279000
Disease: Liver and Intrahepatic Biliary Tract Carcinoma
Liver and Intrahepatic Biliary Tract Carcinoma 		0.030 Biomarker disease BEFREE Myocyte enhancer factor 2D (MEF2D), an oncogene in liver cancer, has been shown to be aberrantly expressed in lung cancer. 29963192 2018
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver 		0.030 Biomarker disease BEFREE Myocyte enhancer factor 2D (MEF2D), an oncogene in liver cancer, has been shown to be aberrantly expressed in lung cancer. 29963192 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.040 AlteredExpression disease BEFREE Myocyte enhancer factor 2D (MEF2D), an oncogene in liver cancer, has been shown to be aberrantly expressed in lung cancer. 29963192 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 AlteredExpression disease BEFREE Myocyte enhancer factor 2D (MEF2D), an oncogene in liver cancer, has been shown to be aberrantly expressed in lung cancer. 29963192 2018
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 AlteredExpression disease BEFREE Myocyte enhancer factor 2D (MEF2D), an oncogene in liver cancer, has been shown to be aberrantly expressed in lung cancer. 29963192 2018
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.060 GeneticVariation disease BEFREE MEF2D fusion genes are newly discovered recurrent gene abnormalities that are detected in approximately 5% of acute lymphoblastic leukemia cases. 30478446 2019
CUI: C1961102
Disease: Precursor Cell Lymphoblastic Leukemia Lymphoma
Precursor Cell Lymphoblastic Leukemia Lymphoma 		0.040 GeneticVariation disease BEFREE MEF2D fusion genes are newly discovered recurrent gene abnormalities that are detected in approximately 5% of acute lymphoblastic leukemia cases. 30478446 2019
CUI: C0018681
Disease: Headache
Headache 		0.100 GeneticVariation phenotype GWASCAT A Genome-Wide Association Study Finds Genetic Associations with Broadly-Defined Headache in UK Biobank (N=223,773). 29397368 2018
CUI: C0014060
Disease: Encephalitis, St. Louis
Encephalitis, St. Louis 		0.010 GeneticVariation disease BEFREE A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. 30459414 2019
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.010 AlteredExpression disease BEFREE All MEF2D-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9. 27507882 2016
CUI: C2004493
Disease: Leukemia, B-Cell
Leukemia, B-Cell 		0.010 AlteredExpression disease BEFREE All MEF2D-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9. 27507882 2016
CUI: C0149931
Disease: Migraine Disorders
Migraine Disorders 		0.130 Biomarker group BEFREE And, MEF2D and ASTN2 also served as genetic risk factors for the migraine without family history. 28058730 2017
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.010 Biomarker group BEFREE As expected, markers of neuronal differentiation such as anti-apoptotic protein B-cell lymphoma 2 (BCL2), myocyte enhancer factor-2D (MEF2D) and zipper protein kinase (MAP3K12; aka ZPK/MUK/DLK) were each up-regulated in response to differentiation. 19666108 2009
CUI: C0149931
Disease: Migraine Disorders
Migraine Disorders 		0.130 GeneticVariation group BEFREE At one extreme, SNPs rs6790925 (near TGFBR2) and rs2274316 (MEF2D) were not associated with migraine overall, MA, or MO but were selective for migraine sub-classified by the presence of one or more of the additional migraine features. 24852292 2014
CUI: C0154723
Disease: Migraine with Aura
Migraine with Aura 		0.010 GeneticVariation disease BEFREE At one extreme, SNPs rs6790925 (near TGFBR2) and rs2274316 (MEF2D) were not associated with migraine overall, MA, or MO but were selective for migraine sub-classified by the presence of one or more of the additional migraine features. 24852292 2014